CLINICAL TRIALS PROFILE FOR DALVANCE
✉ Email this page to a colleague
All Clinical Trials for DALVANCE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02269644 ↗ | A P3 Comparator Trial in Community Acquired Bacterial Pneumonia | Withdrawn | Durata Therapeutics Inc., an affiliate of Allergan plc | Phase 3 | 2015-11-01 | This study will be a double-blind, randomized, multicenter trial to assess the safety and efficacy of a single 1500 mg IV dose of dalbavancin plus a single 500 mg IV dose of azithromycin in comparison to an approved antibiotic regimen of linezolid 600 mg every 12 hours for 10-14 days plus a single 500 mg IV dose of azithromycin for the treatment of Community Acquired Bacterial Pneumonia. |
| NCT02344511 ↗ | Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis | Withdrawn | Durata Therapeutics International BV (an Affiliate of Actavis, Inc.) | Phase 3 | 2016-03-01 | Dalbavancin for Pediatric Osteomyelitis |
| NCT03372941 ↗ | Hospital Avoidance Strategies for ABSSSI | Terminated | Allergan | Phase 4 | 2019-03-04 | More than 40% of patients presenting with acute bacterial skin and skin structure infection (ABSSSI) to the Barnes-Jewish Hospital (BJH) emergency department (ED) are admitted for intravenous antibiotics. There is growing evidence to suggest that many hospital admissions for uncomplicated ABSSSI due to Gram-positive bacteria could be avoided with an alternative treatment strategy employing newer long-acting antibiotics. Coupled with close outpatient follow-up, such an alternative hospital avoidance strategy has the potential to improve quality and value of care for patients with uncomplicated ABSSSI and optimize use of limited inpatient healthcare resources. |
| NCT03372941 ↗ | Hospital Avoidance Strategies for ABSSSI | Terminated | The Foundation for Barnes-Jewish Hospital | Phase 4 | 2019-03-04 | More than 40% of patients presenting with acute bacterial skin and skin structure infection (ABSSSI) to the Barnes-Jewish Hospital (BJH) emergency department (ED) are admitted for intravenous antibiotics. There is growing evidence to suggest that many hospital admissions for uncomplicated ABSSSI due to Gram-positive bacteria could be avoided with an alternative treatment strategy employing newer long-acting antibiotics. Coupled with close outpatient follow-up, such an alternative hospital avoidance strategy has the potential to improve quality and value of care for patients with uncomplicated ABSSSI and optimize use of limited inpatient healthcare resources. |
| NCT03372941 ↗ | Hospital Avoidance Strategies for ABSSSI | Terminated | Washington University School of Medicine | Phase 4 | 2019-03-04 | More than 40% of patients presenting with acute bacterial skin and skin structure infection (ABSSSI) to the Barnes-Jewish Hospital (BJH) emergency department (ED) are admitted for intravenous antibiotics. There is growing evidence to suggest that many hospital admissions for uncomplicated ABSSSI due to Gram-positive bacteria could be avoided with an alternative treatment strategy employing newer long-acting antibiotics. Coupled with close outpatient follow-up, such an alternative hospital avoidance strategy has the potential to improve quality and value of care for patients with uncomplicated ABSSSI and optimize use of limited inpatient healthcare resources. |
| NCT03426761 ↗ | Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections | Recruiting | Johns Hopkins University | Phase 4 | 2018-01-25 | Because of its prolonged terminal half-life, dalbavancin is an extremely attractive option in treating Gram-positive infections caused by S. aureus including MRSA, and streptococcal species. Systemic bacterial infections due to Staphylococci such as osteomyelitis and septic arthritis, are conditions which require prolonged IV therapy, typically for at least 3-6 weeks, though sometimes more. Due to dalbavancin's prolonged terminal half-life, it may offer the opportunity to substantially reduce costs and morbidity in native joint and prosthetic joint infections with one infusion every fourteen days until completion of therapy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DALVANCE
Condition Name
Clinical Trial Locations for DALVANCE
Trials by Country
Clinical Trial Progress for DALVANCE
Clinical Trial Phase
Clinical Trial Sponsors for DALVANCE
Sponsor Name
| Sponsor Name for DALVANCE | |
| Sponsor | Trials |
| University of Colorado, Denver | 1 |
| Durata Therapeutics Inc., an affiliate of Allergan plc | 1 |
| Durata Therapeutics International BV (an Affiliate of Actavis, Inc.) | 1 |
| [disabled in preview] | 3 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
